×
Back to Agenda
Community Discussion of Data Science in Relation to Drug Development
Session Chair(s)
Ruthie Davi, PHD, MS
Senior Vice President, Medidata, a Dassault Systèmes Company, United States
Stella C. Grosser, PHD, MS
Division Director, Office of Biostatistics, OTS, CDER , FDA, United States
This will be a community discussion of data science. Several panelists with experience in the area will be available to share their knowledge.
Learning Objective : At the conclusion of this session, participants should be able to:
- Identify common issues in the overlap between data science, statistics, and drug development
- Describe examples where data science has impacted pharmaceuticals
- Identify techniques of data science to possibly improve the efficiency of drug development
Speaker(s)
Nareen Katta, MBA, MS
Head of Data Science & Analytics, AbbVie, United States
Speaker
Paul Schuette, PHD, MA
Mathematical Statistician, Scientific Computing Coordinator, FDA, United States
Panelist
Matthew Austin, MS
Executive Director, Data Science, Amgen, United States
Speaker
Joan Buenconsejo, PHD, MPH
Head of Cardiovascular and Neuroscience Biostatistics , Bristol Myers Squibb, United States
Panelist
Have an account?